Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.
Fiche publication
Date publication
janvier 2017
Journal
Clinical drug investigation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Pr PIVOT Xavier
Tous les auteurs :
Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, Jary M, Simon P, Pivot X, Blay JY, Limat S
Lien Pubmed
Résumé
The management of advanced gastrointestinal stromal tumors (GISTs) has been modified considerably by the availability of costly tyrosine kinase inhibitors (TKIs); however, the best therapeutic sequence in terms of cost and effectiveness remains unknown.
Mots clés
Cost of Illness, Cost-Benefit Analysis, Drug Costs, Female, Gastrointestinal Neoplasms, drug therapy, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, therapeutic use, Indoles, therapeutic use, Markov Chains, Protein Kinase Inhibitors, therapeutic use, Protein-Tyrosine Kinases, antagonists & inhibitors, Pyrroles, therapeutic use, Quality of Life
Référence
Clin Drug Investig. 2017 Jan;37(1):85-94